FP802 2HCl is an orally active TwinF interface inhibitor with neuroprotective effects. It disrupts the toxicity of the NMDAR/TRPM4 death complex to selectively eliminate eNMDAR-mediated toxicity, suitable for studying Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).

FP802 2HCl (8 μM, 24-72 hours) can effectively dissociate the NMDAR/TRPM4 complex and exert neuroprotective effects in cellular models, though FP802 itself neither directly promotes nor inhibits neurite outgrowth [1].
FP802 2HCl (10 μM, 30 minutes) significantly counteracts the neurotoxicity induced by pennisetum glaucum (20 μM), with an IC50 of 8.7 μM, while restoring NMDA-suppressed immediate early gene expression levels to physiological conditions [2].

FP802 2HCl was administered orally at doses of 10 mg/kg and 40 mg/kg once daily for 4 months, which improved cognitive function in 5xFAD mice, effectively prevented neuronal degeneration, and reduced amyloid pathology in the brain [1].
FP802 2HCl was administered subcutaneously at a dose of 40 mg/kg once daily, starting approximately at week 15, for 4 consecutive weeks. By targeting the NMDAR/TRPM4 complex, it safely delayed the progression of motor neuron degeneration in ALS model mice and significantly extended their survival time [2].